MaxCyte, Inc. License Agreement with Caribou Biosciences (1970M)
May 07 2020 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 1970M
MaxCyte, Inc.
07 May 2020
FOR IMMEDIATE RELEASE
Caribou Biosciences and MaxCyte Enter into Clinical and
Commercial License Agreement
- Agreement enables Caribou to utilize MaxCyte's ExPERT(R)
platform for its CRISPR gene-edited, allogeneic T cell therapy
programs
Berkeley , CA, and GAITHERSBURG, MD, 07 May 2020 - Caribou
Biosciences, Inc. ("Caribou"), a leading CRISPR genome editing
company, and MaxCyte, Inc., (LSE: MXCT), a global cell-based
therapies and life sciences company, today announced a clinical and
commercial license agreement. Under the terms of the agreement,
Caribou gains rights to use MaxCyte's Flow Electroporation(R)
technology and ExPERT platform for the advancement of its CRISPR
gene-edited allogeneic T cell therapy programs.
Caribou will obtain non-exclusive clinical and commercial rights
to use MaxCyte's platform to develop CRISPR gene-edited allogeneic
T cell therapies. In return, MaxCyte will receive undisclosed
development and approval milestones and sales-based payments in
addition to other licensing fees.
"As we advance our lead allogeneic CAR-T cell therapy program,
we are preparing for the future by securing access to a
transfection platform for both clinical and commercial
implementation," said Steven Kanner, Ph.D., Caribou's Chief
Scientific Officer.
Doug Doerfler, President & CEO of MaxCyte, said: "We are
proud to support Caribou Biosciences as it develops its allogeneic
cell therapy programs. This important agreement represents another
key expansion for MaxCyte, emphasizing the value of our technology
platform to companies developing pioneering gene-editing and cell
therapies. We believe that such programs have high potential to
deliver positive clinical impact for patients facing serious and
difficult-to-treat diseases."
MaxCyte's ExPERT instrument family represents the next
generation of leading, clinically validated, electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics.
About Caribou Biosciences, Inc.
Caribou is a leading company in CRISPR genome editing founded by
pioneers of CRISPR biology. The company is developing an internal
pipeline of off-the-shelf CAR-T cell therapies, other gene-edited
cell therapies, and engineered gut microbes. Additionally, Caribou
offers licenses to its CRISPR-Cas9 foundational IP in multiple
fields including research tools, internal research use,
diagnostics, and industrial biotechnology. Interested companies may
contact Caribou at licensing@cariboubio.com . For more information
about Caribou, visit www.cariboubio.com and follow the Company
@CaribouBio. "Caribou Biosciences" and the Caribou logo are
registered trademarks of Caribou Biosciences, Inc.
About MaxCyte
MaxCyte, the clinical-stage global cell-based therapies and life
sciences company, uses its proprietary next-generation cell and
gene therapies to revolutionise medical treatments and ultimately
save lives. The Company's premier cell engineering enabling
technology is currently being deployed by leading drug developers
worldwide, including all of the top ten global biopharmaceutical
companies. MaxCyte licences have been granted to more than 100 cell
therapy programmes, with more than 70 licensed for clinical use,
and the Company has now entered into ten clinical/commercial
license agreements with leading cell therapy and gene editing
developers. MaxCyte was founded in 1998, is listed on the London
Stock Exchange (AIM:MXCT) and is headquartered in Gaithersburg ,
Maryland, US. For more information, visit www.maxcyte.com .
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
Caribou Contact:
Greg Kelley, Ogilvy
gregory.kelley@ogilvy.com
+1 617-761-6724
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-com
Chris Welsh
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRDBGDURSGDGGL
(END) Dow Jones Newswires
May 07, 2020 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024